SG11201808693WA - Anti-il-33 antibodies, compositions, methods and uses thereof - Google Patents
Anti-il-33 antibodies, compositions, methods and uses thereofInfo
- Publication number
- SG11201808693WA SG11201808693WA SG11201808693WA SG11201808693WA SG11201808693WA SG 11201808693W A SG11201808693W A SG 11201808693WA SG 11201808693W A SG11201808693W A SG 11201808693WA SG 11201808693W A SG11201808693W A SG 11201808693WA SG 11201808693W A SG11201808693W A SG 11201808693WA
- Authority
- SG
- Singapore
- Prior art keywords
- rule
- international
- massachusetts
- april
- pct
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Dermatology (AREA)
- Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization 11111111111111111111111111111111111111111111111111111111111111111111111111 International Bureau (10) International Publication Number (43) International Publication Date ......0\"\" WO 2017/187307 Al 02 November 2017 (02.11.2017) WIP0 I PCT (51) International Patent Classification: C07K 16/24 (2006.01) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (21) International Application Number: PCT/IB2017/052282 (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (22) International Filing Date: 20 April 2017 (20.04.2017) GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (25) Filing Language: English EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (26) Publication Language: English MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (30) Priority Data: KM, ML, MR, NE, SN, TD, TG). 62/328,294 27 April 2016 (27.04.2016) US 62/483,781 10 April 2017 (10.04.2017) US Declarations under Rule 4.17: (71) Applicant: PFIZER INC. [US/US]; 235 East 42nd Street, — as to the identity of the inventor (Rule 4.17(i)) — as to applicant's entitlement to apply for and be granted a New York, New York 10017 (US). patent (Rule 4.17(0 (72) Inventors: BLOOM, Laird; 82 Falcon St., Needham, Massachusetts 02492 (US). NOCKA, Karl Henry; 84 — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Shaker Road, Harvard, Massachusetts 01451 (US). AP- Published: GAR, James Reasoner; 92 Cotton St., Newton, Massa- chusetts 02458 (US). FARMER, Mark A.; 8 Taylor Rd., — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the North Reading, Massachusetts 01864 (US). LAMBERT, Matthew Allister; 13 Gainsborough Court, Malahide, Dublin (IE). claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) — with (an) indication(s) in relation to deposited biological = (74) Agent: WALDRON, Roy F.; Pfizer Inc., 235 East 42nd Street, MS 235/9/S20, New York, NY 10017 (US). material furnished under Rule 13bis separately from the description (Rules 13bis.4(d)(i) and 48.2 (a)(viii)) Designated States (unless otherwise indicated, for every — with sequence listing part of description (Rule 5.2(a)) = (81) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, _ DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, = HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, _ = _ = = = Title: ANTI-IL-33 ANTIBODIES, COMPOSITIONS, METHODS AND USES THEREOF (57) : The invention provides antibodies, and anti- gen-binding fragments thereof, that specifically bind to IL-33, as well as uses, and associated methods thereof. = (54) = = 17 17 IL33mm2 — 14 - .4 IN VS 1 Sk A i )1.33WT DTI' e B © en ; 5 f IL-1alpha, IL-1beta, I L-33WT, !L- 36alpha, IL-36 gamma, rhIL18 IN , GC 11 350 400 4S0 500 550 600 IN Time 3 Il 0 FIG. 3A N O
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662328294P | 2016-04-27 | 2016-04-27 | |
US201762483781P | 2017-04-10 | 2017-04-10 | |
PCT/IB2017/052282 WO2017187307A1 (en) | 2016-04-27 | 2017-04-20 | Anti-il-33 antibodies, compositions, methods and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201808693WA true SG11201808693WA (en) | 2018-11-29 |
Family
ID=58632552
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201808693WA SG11201808693WA (en) | 2016-04-27 | 2017-04-20 | Anti-il-33 antibodies, compositions, methods and uses thereof |
Country Status (17)
Country | Link |
---|---|
US (2) | US10544212B2 (en) |
EP (1) | EP3448888A1 (en) |
JP (1) | JP2019516362A (en) |
KR (1) | KR20180128028A (en) |
CN (1) | CN109415436A (en) |
AU (1) | AU2017257330A1 (en) |
BR (1) | BR112018071276A2 (en) |
CA (1) | CA2965089A1 (en) |
CO (1) | CO2018011364A2 (en) |
IL (1) | IL262497A (en) |
MX (1) | MX2018013038A (en) |
PE (1) | PE20181952A1 (en) |
PH (1) | PH12018502225A1 (en) |
RU (1) | RU2740309C2 (en) |
SG (1) | SG11201808693WA (en) |
TW (2) | TWI679211B (en) |
WO (1) | WO2017187307A1 (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA201791029A1 (en) | 2014-11-10 | 2017-12-29 | Дженентек, Инк. | ANTIBODIES AGAINST INTERLEUKIN-33 AND THEIR APPLICATION |
CN107109494B (en) | 2014-11-10 | 2023-10-27 | 豪夫迈·罗氏有限公司 | Methods of treatment and diagnosis of IL-33 mediated diseases |
CN110997725A (en) | 2017-06-12 | 2020-04-10 | 蓝鳍生物医药公司 | anti-IL 1RAP antibodies and antibody drug conjugates |
AU2019243665B2 (en) * | 2018-03-30 | 2023-06-01 | Merus N.V. | Multivalent antibody |
IL307286A (en) | 2018-04-11 | 2023-11-01 | Regeneron Pharma | Methods and compositions for quantifying il-33 |
CN113194994A (en) * | 2018-12-11 | 2021-07-30 | 开拓免疫医疗公司 | Methods of using anti-TREM 2 antibodies |
CN112480252B (en) * | 2019-09-12 | 2023-02-07 | 上海麦济生物技术有限公司 | Anti-interleukin-33 antibody and preparation method and application thereof |
KR20220092927A (en) * | 2019-11-04 | 2022-07-04 | 메디뮨 리미티드 | Anti-IL-33 Therapeutics to Treat Renal Disorders |
CA3158323A1 (en) | 2019-11-04 | 2021-05-14 | Medimmune Limited | Methods of using il-33 antagonists |
WO2021180858A1 (en) | 2020-03-13 | 2021-09-16 | Medimmune Limited | Therapeutic methods for the treatment of subjects with risk alelles in il33 |
IL296256A (en) | 2020-03-13 | 2022-11-01 | Genentech Inc | Anti-interleukin-33 antibodies and uses thereof |
CA3176571A1 (en) * | 2020-04-06 | 2021-10-14 | Medimmune Limited | Treating acute respiratory distress syndrome with il-33 axis binding antagonists |
IL297841A (en) | 2020-05-11 | 2023-01-01 | Medimmune Ltd | Formulations of anti-il-33 antibodies |
CN111620948B (en) * | 2020-06-10 | 2022-04-08 | 南京赛新生物科技有限公司 | Antibodies to IL-33 |
KR20220022226A (en) * | 2020-08-18 | 2022-02-25 | 성균관대학교산학협력단 | Il-33 binding antibodies or antigen binding fragments thereof |
CN113603775B (en) * | 2021-09-03 | 2022-05-20 | 江苏荃信生物医药股份有限公司 | Anti-human interleukin-33 monoclonal antibody and application thereof |
WO2023108101A1 (en) * | 2021-12-09 | 2023-06-15 | Emory University | Antibodies that inhibit glycoprotein ib-ix mediated platelet signaling and uses in managing bleeding conditions |
CN114397289A (en) * | 2022-01-14 | 2022-04-26 | 长春工业大学 | Quantitative analysis method for heavy metal elements in soil and related equipment |
WO2023160610A1 (en) * | 2022-02-24 | 2023-08-31 | Sinomab Bioscience Limited | Bispecific binding proteins against alarmins and uses thereof |
TW202402790A (en) | 2022-03-25 | 2024-01-16 | 英商梅迪繆思有限公司 | Methods for reducing respiratory infections |
WO2024038185A1 (en) | 2022-08-19 | 2024-02-22 | Medimmune Limited | Method of selecting patients for treatment with an il-33 axis antagonist |
CN115947844B (en) * | 2022-12-09 | 2024-06-14 | 江苏荃信生物医药股份有限公司 | Novel anti-human IL-33 monoclonal antibody, kit containing same and detection method thereof |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
DE60226641D1 (en) | 2001-12-03 | 2008-06-26 | Amgen Fremont Inc | ANTIBODY CATEGORIZATION BASED ON BINDING CHARACTERISTICS |
PT2270048E (en) | 2002-12-24 | 2016-02-10 | Rinat Neuroscience Corp | Anti-ngf antibodies and methods using same |
NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
CA2686683A1 (en) | 2007-05-18 | 2008-11-27 | Medimmune, Llc | Il-33 in inflammatory disease |
NZ588853A (en) | 2008-03-31 | 2013-07-26 | Genentech Inc | Compositions and methods for treating and diagnosing asthma |
EP2475388B1 (en) | 2009-09-10 | 2017-11-08 | Merck Sharp & Dohme Corp. | Use of il-33 antagonists to treat fibrotic disease |
EP3447491A3 (en) | 2010-12-16 | 2019-06-05 | F. Hoffmann-La Roche AG | Diagnosis and treatments relating to th2 inhibition |
JP6147674B2 (en) | 2011-02-23 | 2017-06-14 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Antibodies against human IL33R and uses thereof |
FR2972006B1 (en) | 2011-02-24 | 2016-03-25 | Centre Nat Rech Scient | NOVEL IL-33 SUPERACTIVE FRAGMENTS AND USES THEREOF |
US9260756B2 (en) | 2012-02-24 | 2016-02-16 | Children's Hospital Medical Center | Esophageal microRNA expression profiles in eosinophilic esophagitis |
JO3623B1 (en) | 2012-05-18 | 2020-08-27 | Amgen Inc | St2 antigen binding proteins |
WO2014044681A1 (en) | 2012-09-19 | 2014-03-27 | Innate Pharma | Kir3dl2 binding agents |
WO2014062621A1 (en) | 2012-10-15 | 2014-04-24 | Stc.Unm | Treatment of autophagy-based disorders and related pharmaceutical compositions, diagnostic and screening assays and kits |
JO3532B1 (en) * | 2013-03-13 | 2020-07-05 | Regeneron Pharma | Anti-il-33 antibodies and uses thereof |
AU2014240101B2 (en) | 2013-03-15 | 2018-05-17 | Regeneron Pharmaceuticals, Inc. | IL-33 antagonists and uses thereof |
BR112016013347B1 (en) * | 2013-12-26 | 2023-12-12 | Mitsubishi Tanabe Pharma Corporation | ANTI-IL-33 NEUTRALIZING HUMAN MONOCLONAL ANTIBODY, PHARMACEUTICAL COMPOSITION, INHIBITOR OF CYTOKINE EXPRESSION, NUCLEIC ACID MOLECULE, VECTOR, TRANSGENIC BACTERIAL CELL, METHOD OF PRODUCTION AND USE THEREOF |
RU2019118984A (en) * | 2014-01-10 | 2019-08-06 | Анаптисбайо, Инк. | ANTIBODIES AIMED AGAINST INTERLEUKIN-33 (IL-33) |
US10040859B2 (en) | 2014-04-21 | 2018-08-07 | The Children's Hospital Of Philadelphia | Methods of treating hemophagocytic lymphohistiocytosis with an IL-33 receptor antibody |
CN107109494B (en) | 2014-11-10 | 2023-10-27 | 豪夫迈·罗氏有限公司 | Methods of treatment and diagnosis of IL-33 mediated diseases |
EA201791029A1 (en) | 2014-11-10 | 2017-12-29 | Дженентек, Инк. | ANTIBODIES AGAINST INTERLEUKIN-33 AND THEIR APPLICATION |
BR112017020955A2 (en) | 2015-03-31 | 2018-07-10 | Medimmune Limited | il33 form, mutated il33 forms, antibodies, assays and methods of use thereof |
EA201890891A1 (en) | 2015-10-06 | 2018-09-28 | Ридженерон Фармасьютикалз, Инк. | BIOMARKERS ASSOCIATED WITH INTERLEYKIN-33 DISEASES, AND THEIR APPLICATION |
SG10202006699XA (en) | 2016-01-14 | 2020-08-28 | Anaptysbio Inc | Inhibition of allergic reaction using an il-33 inhibitor |
-
2017
- 2017-04-20 PE PE2018002029A patent/PE20181952A1/en unknown
- 2017-04-20 BR BR112018071276-0A patent/BR112018071276A2/en not_active IP Right Cessation
- 2017-04-20 EP EP17719350.5A patent/EP3448888A1/en not_active Withdrawn
- 2017-04-20 SG SG11201808693WA patent/SG11201808693WA/en unknown
- 2017-04-20 KR KR1020187030715A patent/KR20180128028A/en active IP Right Grant
- 2017-04-20 WO PCT/IB2017/052282 patent/WO2017187307A1/en active Application Filing
- 2017-04-20 RU RU2018137811A patent/RU2740309C2/en active
- 2017-04-20 AU AU2017257330A patent/AU2017257330A1/en not_active Abandoned
- 2017-04-20 CN CN201780026021.2A patent/CN109415436A/en active Pending
- 2017-04-20 JP JP2018555761A patent/JP2019516362A/en active Pending
- 2017-04-20 MX MX2018013038A patent/MX2018013038A/en unknown
- 2017-04-24 TW TW106113637A patent/TWI679211B/en not_active IP Right Cessation
- 2017-04-24 CA CA2965089A patent/CA2965089A1/en not_active Abandoned
- 2017-04-24 TW TW108128620A patent/TW201943729A/en unknown
- 2017-04-24 US US15/495,172 patent/US10544212B2/en active Active
-
2018
- 2018-10-18 PH PH12018502225A patent/PH12018502225A1/en unknown
- 2018-10-21 IL IL262497A patent/IL262497A/en unknown
- 2018-10-24 CO CONC2018/0011364A patent/CO2018011364A2/en unknown
-
2019
- 2019-12-29 US US16/729,421 patent/US20200308272A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20180037644A1 (en) | 2018-02-08 |
US10544212B2 (en) | 2020-01-28 |
BR112018071276A2 (en) | 2019-02-12 |
CO2018011364A2 (en) | 2018-11-13 |
CN109415436A (en) | 2019-03-01 |
EP3448888A1 (en) | 2019-03-06 |
KR20180128028A (en) | 2018-11-30 |
AU2017257330A1 (en) | 2018-10-18 |
TW201808995A (en) | 2018-03-16 |
TW201943729A (en) | 2019-11-16 |
WO2017187307A1 (en) | 2017-11-02 |
IL262497A (en) | 2018-12-31 |
PE20181952A1 (en) | 2018-12-17 |
JP2019516362A (en) | 2019-06-20 |
MX2018013038A (en) | 2019-03-28 |
RU2740309C2 (en) | 2021-01-13 |
RU2018137811A3 (en) | 2020-05-27 |
RU2018137811A (en) | 2020-05-27 |
PH12018502225A1 (en) | 2019-08-19 |
TWI679211B (en) | 2019-12-11 |
US20200308272A1 (en) | 2020-10-01 |
CA2965089A1 (en) | 2017-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201808693WA (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
SG11201804161VA (en) | Compositions comprising bacterial strains | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
SG11201909941QA (en) | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201807489PA (en) | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore | |
SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
SG11201403106SA (en) | Anti-phf-tau antibodies and their uses | |
SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
SG11201406963RA (en) | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer | |
SG11201406977TA (en) | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer | |
SG11201804673WA (en) | Novel anti-claudin antibodies and methods of use | |
SG11201408153YA (en) | Prostate-specific membrane antigen antibody drug conjugates | |
SG11201808554TA (en) | Integral membrane protein display on poxvirus extracellular enveloped virions | |
SG11201906853QA (en) | Anti-rsv monoclonal antibody formulation | |
SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
SG11201804704PA (en) | Compositions and methods for decreasing tau expression |